交银国际每日晨报-20250703

Group 1: Northern Huachuang (北方华创) - The company is positioned as a leading domestic semiconductor equipment manufacturer, showcasing both growth potential and resilience [1] - The domestic semiconductor equipment market share in China has increased from 13% in 2015 to an estimated 42% in 2024, with Northern Huachuang expected to double its market share by 2025 compared to 2020 [2] - The company’s current valuation at 27 times NTM P/E is close to historical lows, suggesting an attractive investment opportunity with a target price of RMB 530, indicating a potential upside of 19.6% [2] Group 2: Genscript Biotech (云顶新耀) - The company is advancing its platform for reversible mRNA therapies, with promising data from multiple drug candidates [3] - The EVM16 candidate has shown efficacy in mouse models and demonstrated synergy with PD-1 antibodies, while EVM14 is progressing through preclinical studies with potential for inducing immune memory [4] - The EVER001 study for treating membranous nephropathy has reported significant immunological responses, with antibody levels dropping by over 60% after 8-12 weeks [4][7] Group 3: Photovoltaic Industry - Recent policy discussions indicate a shift towards addressing the challenges faced by the photovoltaic industry, with expectations for substantive policies to emerge [8] - The report highlights opportunities for leading photovoltaic manufacturers, particularly in glass and silicon production, as the industry seeks to overcome competitive pressures [8] Group 4: Automotive Industry - The report notes a slowdown in the month-on-month growth of new energy vehicle deliveries, with a 17.7% year-on-year increase across 11 manufacturers [9] - BYD's June sales reached 377,628 units, reflecting an 11% year-on-year growth, while Xiaomi's deliveries exceeded 25,000 units despite slight month-on-month declines [10][11] - The overall market is expected to continue its growth trajectory in July, driven by new model launches from various manufacturers [11]